CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
自体树突状疫苗治疗转移性肾癌：ADAPT 试验及其后续
英文原题：Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond.
查看英文原题
Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
根据大型ADAPT试验的结果，自体树突细胞疫苗疗法联合全身治疗可能对接受减瘤性肾切除术的转移性肾细胞癌患者有益。回顾性分析联合相关免疫学研究显示，接受everolimus的患者可能获益更大。目前正在入组的2期CoImmune试验旨在减瘤性肾切除术并接受全身治疗的患者中验证这一假设。
展开英文摘要原文
Autologous dendritic-cell vaccine therapy combined with systemic therapy may be of benefit in patients with metastatic renal cell cancer undergoing cytoreductive nephrectomy according to results from the large ADAPT trial. Combined retrospective analysis and correlative immunology research revealed that patients receiving everolimus may have derived a greater benefit. The currently enrolling phase 2 CoImmune trial is designed to test this hypothesis in patients undergoing cytoreductive nephrectomy and systemic therapy.
论文信息
- 作者
- Master VA、Uzzo RG、Bratlavsky G、Karam JA
- 单位
- Winship Cancer Institute, Emory University, Atlanta, GA, USA. Electronic address: vmaster@emory.edu.United States
- 文献类型
- 临床试验
- 期刊
- European urology focus2022 May
- 原文标识
- PubMed 35662502 · DOI 10.1016/j.euf.2022.04.003